AstraZeneca (AZN) Reports FDA Acceptance of Supplemental Biologics License Application for IMFINZI (Durvalumab)
Tweet Send to a Friend
AstraZeneca (NYSE: AZN) and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
